Immune reconstitution prevents metastatic recurrence of murine osteosarcoma.
Primary tumors developing in immunocompetent hosts escape immunosurveillance by acquiring immune evasive properties. This raises the prospect that metastases derived from such tumors will also evade immunity. To investigate whether immune surveillance plays a role in preventing metastases, we studied a murine model which mimics the clinical progression of osteosarcoma: primary tumor growth in the lower extremity, amputation, minimal residual disease followed by the development of overt metastases. K7M2 implants readily escaped immune surveillance since normal BALB/c mice, T cell deficient SCID and T/NK cell deficient SCID-bg mice showed no difference in the rate of growth of primary osteosarcomas. However, both SCID and SCID-bg mice had higher rates of metastases than immunocompetent mice. Similarly, immune reconstitution following transfer of naive T cells to SCID or SCID-bg mice did not impact primary tumor growth, but significantly diminished metastatic recurrence. T cells in osteosarcoma bearing mice produced IFNgamma in response to tumor and IFNgamma production by immune reconstituting T cells was required to prevent metastases. These results demonstrate an important role for T cell based immune surveillance in preventing metastases, even when metastases develop from tumors that adeptly evade immunosurveillance. The results further suggest that T cell depleting cancer therapies may eliminate beneficial immune responses and that immune reconstitution of lymphopenic cancer patients could prevent metastatic recurrence of solid tumors.
Merchant
Melinda S
MS
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
Melchionda
Fraia
F
Sinha
Manoj
M
Khanna
Chand
C
Helman
Lee
L
Mackall
Crystal L
CL
D000818:Animals; D001859:Bone Neoplasms / Q000276:immunology* / Q000473:pathology; D007157:Immunologic Surveillance; D051379:Mice; D016513:Mice, SCID; D009362:Neoplasm Metastasis / Q000276:immunology / Q000517:prevention & control*; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D012516:Osteosarcoma / Q000276:immunology* / Q000556:secondary; D013601:T-Lymphocytes / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology*